SYDNEY, Australia, 8 November 2024: Imugene Limited (ASX), a clinical-stage immunooncology company, is pleased to announce the opening of the first Australian site for its azer-cel (azercabtagene zapreleucel) Phase 1b clinical trial. The Royal Prince Alfred Hospital in Sydney will begin patient recruitment in November 2024, The Royal Prince Alfred Hospital in Sydney is the first Australian site for the Phase 1b trial, with patient recruitment starting in November 2024 • The trial is Australia’s only actively enrolling allogeneic CAR T-cell trial and is focused on relapsed or refractory diffuse large B-cell lymphoma (DLBCL) This is the first of up to five sites we plan to open in Australia, as we seek to speed up enrolment and deliver improved outcomes in this form of blood cancer.”
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)